Joas, Erik http://orcid.org/0000-0001-9546-2192
Jonsson, Lina
Viktorin, Alexander http://orcid.org/0000-0003-2141-2816
Smedler, Erik http://orcid.org/0000-0003-4609-3620
Pålsson, Erik
Goodwin, Guy M. http://orcid.org/0000-0002-1426-2816
Landén, Mikael http://orcid.org/0000-0002-4496-6451
Funding for this research was provided by:
Kungl. Vetenskaps- och Vitterhets-Samhället
Stiftelsen för Strategisk Forskning (KF10-0039)
Vetenskapsrådet (2018-02653)
Wenner-Gren Foundation (SSv2019-0008)
Article History
Received: 23 March 2022
Revised: 13 September 2022
Accepted: 30 September 2022
First Online: 4 November 2022
Competing interests
: EJ is currently employed at IQVIA which is a contract research organization that perform commissioned pharmacoepidemiological studies, and therefore is collaborating with several pharmaceutical companies. Employment began June 1st 2022 after this study was submitted to the journal. GMG reports personal fees from Servier, personal fees from Lundbeck, personal fees from Medscape, personal fees from P1Vital, personal fees from Compass pathways, personal fees from Johnson&Johnson/Janssen, personal fees from Sage Therapeutics, personal fees from Novartis, outside the submitted work. ML reports grants from The Swedish Foundation for Strategic Research, grants from The Swedish Medical Research council, grants from The Swedish Federal Government under the LUA/ALF agreement during the conduct of the study; personal fees from Lundbeck pharmaceuticals outside the submitted work. All other authors report nothing to disclose.